title: Comparison of human immunodeficiency virus type 1 tropism profiles in clinical samples by the Trofile and MT-2 assays.
abstract: The recent availability of CCR5 antagonists as anti-human immunodeficiency virus (anti-HIV) therapeutics has highlighted the need to accurately identify CXCR4-using variants in patient samples when use of this new drug class is considered. The Trofile assay (Monogram Biosciences) has become the method that is the most widely used to define tropism in the clinic prior to the use of a CCR5 antagonist. By comparison, the MT-2 assay has been used since early in the HIV epidemic to define tropism in clinical specimens. Given that there are few data from direct comparisons of these two assays, we evaluated the performance of the plasma-based Trofile assay and the peripheral blood mononuclear cell (PBMC)-based MT-2 assay for the detection of CXCR4 use in defining the tropism of HIV isolates derived from clinical samples. The various samples used for this comparison were derived from participants of the Amsterdam Cohort Studies on HIV infection and AIDS who underwent consecutive MT-2 assay testing of their PBMCs at approximately 3-month intervals. This unique sample set was specifically selected because consecutive MT-2 assays had demonstrated a shift from negative to positive in PBMCs, reflecting the first emergence of CXCR4-using virus in PBMCs above the level of detection of the assay in these individuals. Trofile testing was performed with clonal HIV type 1 (HIV-1) variants (n = 21), MT-2 cell culture-derived cells (n = 20) and supernatants (n = 42), and plasma samples (n = 76). Among the clonal HIV-1 variants and MT-2 cell culture-derived samples, the results of the Trofile and MT-2 assays demonstrated a high degree of concordance (95% to 98%). Among consecutive plasma samples, detection of CXCR4-using virus was at or before the time of first detection by the MT-2 assay in 5/10 patients by the original Trofile assay and in 9/10 patients by the enhanced-sensitivity Trofile assay. Differences in the time to the first detection of CXCR4 use between the MT-2 assay (PBMCs) and the original Trofile assay (plasma) were greatly reduced by the enhanced-sensitivity Trofile assay, suggesting that sensitivity for the detection of minor CXCR4-using variants may be a more important determinant of discordant findings than compartmentalization. The similarities in performance of the enhanced-sensitivity Trofile and MT-2 assays suggest that either may be an appropriate methodology to define tropism in patient specimens.
authors.affiliation: Monogram Biosciences, Clinical Research, South San Francisco, California, USA.
authors.forename: Eoin
authors.initials: E
authors.lastname: Coakley
authors.forename: Jacqueline D
authors.initials: JD
authors.lastname: Reeves
authors.forename: Wei
authors.initials: W
authors.lastname: Huang
authors.forename: Marga
authors.initials: M
authors.lastname: Mangas-Ruiz
authors.forename: Irma
authors.initials: I
authors.lastname: Maurer
authors.forename: Agnes M
authors.initials: AM
authors.lastname: Harskamp
authors.forename: Soumi
authors.initials: S
authors.lastname: Gupta
authors.forename: Yolanda
authors.initials: Y
authors.lastname: Lie
authors.forename: Christos J
authors.initials: CJ
authors.lastname: Petropoulos
authors.forename: Hanneke
authors.initials: H
authors.lastname: Schuitemaker
authors.forename: Angélique B
authors.initials: AB
authors.lastname: van 't Wout
mesh_terms: D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000821:virology*; D010949:Plasma / Q000821:virology*; D019718:Receptors, CXCR4 / Q000502:physiology; D056189:Viral Tropism
chemical_list: C527276:CXCR4 protein, human; D019718:Receptors, CXCR4
references.citation: J Virol. 1998 Jun;72(6):5099-107
references.pmid: 9573281
references.citation: J Infect Dis. 2005 Aug 1;192(3):466-74
references.pmid: 15995960
references.citation: Ann Intern Med. 1993 May 1;118(9):681-8
references.pmid: 8096374
references.citation: J Clin Microbiol. 1994 Sep;32(9):2291-4
references.pmid: 7814561
references.citation: J Infect Dis. 1994 May;169(5):968-74
references.pmid: 7909549
references.citation: J Virol. 1992 May;66(5):3183-7
references.pmid: 1560543
references.citation: Nat Med. 1999 Mar;5(3):344-6
references.pmid: 10086394
references.citation: J Virol. 1988 Jun;62(6):2026-32
references.pmid: 3130494
references.citation: Science. 1996 May 10;272(5263):872-7
references.pmid: 8629022
references.citation: J Infect Dis. 1996 Feb;173(2):349-54
references.pmid: 8568295
references.citation: Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1925-30
references.pmid: 9050881
references.citation: Nature. 1998 Jan 15;391(6664):240
references.pmid: 9440686
references.citation: J Clin Invest. 2000 Oct;106(8):1039-52
references.pmid: 11032864
references.citation: J Infect Dis. 2007 Jul 15;196(2):304-12
references.pmid: 17570119
references.citation: Science. 1996 Jun 28;272(5270):1955-8
references.pmid: 8658171
references.citation: J Virol. 1988 Nov;62(11):4414-9
references.pmid: 2459416
references.citation: J Infect Dis. 2006 Oct 1;194(7):926-30
references.pmid: 16960780
references.citation: Nat Protoc. 2008;3(3):363-70
references.pmid: 18323807
references.citation: J Infect Dis. 2005 Mar 15;191(6):866-72
references.pmid: 15717260
references.citation: Antimicrob Agents Chemother. 2007 Feb;51(2):566-75
references.pmid: 17116663
references.citation: J Infect Dis. 1993 Dec;168(6):1374-9
references.pmid: 7902382
references.citation: Nat Med. 1997 Mar;3(3):338-40
references.pmid: 9055864
references.citation: J Immunol. 1998 Oct 1;161(7):3702-10
references.pmid: 9759895
references.citation: N Engl J Med. 2008 Oct 2;359(14):1429-41
references.pmid: 18832244
references.citation: AIDS. 1998 May 7;12(7):729-36
references.pmid: 9619804
references.citation: J Virol. 2007 Oct;81(19):10232-41
references.pmid: 17652386
references.citation: Clin Infect Dis. 2007 Feb 15;44(4):591-5
references.pmid: 17243065
references.citation: J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):267-75
references.pmid: 16249699
references.citation: Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1269-74
references.pmid: 10655520
references.citation: Virology. 1989 Jul;171(1):149-55
references.pmid: 2472701
references.citation: J Virol. 1997 Oct;71(10):7478-87
references.pmid: 9311827
references.citation: J Virol. 2001 Nov;75(21):10455-9
references.pmid: 11581413
references.citation: AIDS. 2008 Jul 31;22(12):1411-5
references.pmid: 18614863
references.citation: Nature. 1996 Jun 20;381(6584):661-6
references.pmid: 8649511
references.citation: J Virol. 1992 Nov;66(11):6777-80
references.pmid: 1404617
references.citation: AIDS. 1992 Jan;6(1):49-54
references.pmid: 1543566
references.citation: J Virol. 1997 Apr;71(4):2705-14
references.pmid: 9060623
references.citation: Nature. 1996 Jun 20;381(6584):667-73
references.pmid: 8649512
references.citation: J Infect Dis. 2009 Dec 1;200(11):1724-8
references.pmid: 19874179
references.citation: J Infect Dis. 2006 Jul 15;194(2):238-46
references.pmid: 16779731